SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~November~~February ~~2025~~2026

Commission file number: 001-35223

BioLineRx Ltd.

(Translation of registrant’s name into English)

2 HaMa’ayan Street

Modi’in 7177871, Israel

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On ~~November~~February 2422, ~~2025~~2026, in binding arbitration, the ~~Registrant~~arbitrator issued a ~~press~~final ~~release~~award ~~announcing~~in ~~its~~favor ~~financial~~of ~~results~~BioLineRx ~~for~~Ltd. (the ~~three~~“Company”), ~~and~~denying ~~nine~~all ~~months~~claims ~~ended~~asserted ~~September~~against ~~30,~~it ~~2025~~by Biokine Therapeutics Ltd. ~~The~~(“Biokine”) ~~Registrant~~and awarding isthe ~~also~~Company ~~publishing~~expenses, ~~its~~including ~~unaudited interim~~legal ~~consolidated~~fees. ~~financial~~As ~~statements~~previously disclosed, asin ~~well~~June as2024, ~~its~~Biokine ~~operating~~filed ~~and~~a ~~financial~~complaint ~~review,~~against asthe ofCompany ~~September~~alleging ~~30,~~breach ~~2025~~of contract and ~~for~~the purported failure to make certain payments to Biokine under the Company’s ~~three~~in-licensing ~~and~~agreement ~~nine~~with ~~months~~Biokine ~~then~~for ~~ended~~motixafortide. ~~Attached~~The ~~hereto~~complaint, ~~are~~as ~~the~~subsequently ~~following~~amended, ~~exhibits:~~sought damages of approximately $7.2 million and declaratory judgment in favor of Biokine.

~~Exhibit~~This 1:Report ~~Registrant’s~~on ~~press~~Form ~~release~~6-K ~~dated~~is ~~November~~hereby ~~24,~~incorporated ~~2025;~~by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Exhibit 2: Registrant’s condensed consolidated interim financial statements as of September 30, 2025 and for the three and nine months then ended; and

Exhibit 3: Registrant’s operating and financial review as of September 30, 2025 and for the three and nine months then ended.

This Form 6-K, the text under the heading “Financial Results for the Quarter Ended September 30, 2025” in Exhibit 1, Exhibit 2 and Exhibit 3 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioLineRx Ltd.

	By:	/s/ Philip A. Serlin
		Philip A. Serlin
		Chief Executive Officer

Dated: ~~November~~February 2423, ~~2025~~2026

Filing Compare · BioLineRx Ltd.